Arvita Therapeutics
Arvita is a therapeutics company developing Life-changing therapies that improve quality of life for people with inherited cancer risk.
mRNA Vaccines in Hereditary disease
At Arvita Therapeutics, we focus on patients living with hereditary cancer predisposition. We believe cancers that arise from inherited risk may be especially well suited to immunotherapy because they often develop through recurring patterns of genetic change. These shared changes can create common targets across patients, making it possible to design preventive therapies that may benefit broader patient groups.
Our first focus: Neurofibromatosis Type 1
• Arvita Therapeutics is developing mRNA-based vaccines for tumours commonly found in individuals with Neurofibromatosis Type 1 (NF1).
• Our approach focuses on identifying shared tumour antigens that may be targeted across groups of NF1 patients.
• By targeting these shared features, we aim to create therapeutic options that could benefit the broader NF1 patient population.
• We are also exploring mRNA therapeutics that target disease-associated changes in gene expression.
Tumour Antigen & Target Discovery
Cancer cells express unique proteins on their surface called tumour-specific antigens (TSAs) or neoantigens. These antigens can act as targetable flags, to focus the immune system to recognize and target cancer cells.
Our research leverages genome sequencing, proteomics and bioinformatics to identify shared tumour antigens common to specific subtypes of cancer.
NF1 is such a hereditary cancer predisposition. By pinpointing these common targets, we aim to develop a vaccine with broad applicability across NF1 patients while also developing personalized approaches for each patient when necessary.
mRNA Vaccine Design & Optimization
Once identified, these shared tumour antigens become the blueprints for our mRNA vaccine. We use in-house proprietary Artificial Intelligence pipelines to design and synthesize mRNA sequences encoding these antigens, optimizing them for efficient delivery, safety and robust immune response.
Preclinical Validation & Clinical Development
We utilize preclinical models that closely mimic NF1-associated tumours to assess the vaccine's ability to trigger a targeted immune response and control tumour growth. Promising preclinical data will pave the way for Investigational New Drug (IND) application and subsequent clinical trials to evaluate the safety and efficacy of the vaccine in humans with NF1.
Join the Team
At Arvita Therapeutics, we're on a mission to make a meaningful impact in the fight against NF1 and childhood tumors. We believe in the power of science and innovation to transform lives.
We're looking for passionate, driven individuals to join our team as we pioneer new therapies and push the boundaries of what's possible in biotech.
If you're ready to be part of a dynamic, purpose-driven organization where your work will directly contribute to improving children's health, we want to hear from you.
